408 related articles for article (PubMed ID: 15378443)
1. Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease.
Litt DJ; Savino S; Beddek A; Comanducci M; Sandiford C; Stevens J; Levin M; Ison C; Pizza M; Rappuoli R; Kroll JS
J Infect Dis; 2004 Oct; 190(8):1488-97. PubMed ID: 15378443
[TBL] [Abstract][Full Text] [Related]
2. Assessment of vaccine potential of the Neisseria-specific protein NMB0938.
Sardiñas G; Climent Y; Rodríguez Y; González S; García D; Cobas K; Caballero E; Pérez Y; Brookes C; Taylor S; Gorringe A; Delgado M; Pajón R; Yero D
Vaccine; 2009 Nov; 27(49):6910-7. PubMed ID: 19751688
[TBL] [Abstract][Full Text] [Related]
3. Neisseria meningitidis, Neisseria lactamica and Moraxella catarrhalis share cross-reactive carbohydrate antigens.
Braun JM; Beuth J; Blackwell CC; Giersen S; Higgins PG; Tzanakaki G; Unverhau H; Weir DM
Vaccine; 2004 Feb; 22(7):898-908. PubMed ID: 15040943
[TBL] [Abstract][Full Text] [Related]
4. Can Neisseria lactamica antigens provide an effective vaccine to prevent meningococcal disease?
Gorringe AR
Expert Rev Vaccines; 2005 Jun; 4(3):373-9. PubMed ID: 16026250
[TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis.
Jacobsson S; Mölling P; Olcén P
Vaccine; 2009 Sep; 27(42):5755-9. PubMed ID: 19654065
[TBL] [Abstract][Full Text] [Related]
6. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.
Li Y; Zhang Q; Winterbotham M; Mowe E; Gorringe A; Tang CM
Infect Immun; 2006 Nov; 74(11):6348-55. PubMed ID: 16966413
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional regulation of the nadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine.
Fagnocchi L; Biolchi A; Ferlicca F; Boccadifuoco G; Brunelli B; Brier S; Norais N; Chiarot E; Bensi G; Kroll JS; Pizza M; Donnelly J; Giuliani MM; Delany I
Infect Immun; 2013 Feb; 81(2):560-9. PubMed ID: 23230289
[TBL] [Abstract][Full Text] [Related]
8. Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage.
Ala'aldeen DA; Flint M; Oldfield NJ; Omer SA; McNeil LK; Jiang Q; Murphy E; Giardina PC; Novikova EG; Dodge-Scully IL; Bayliss CD; Turner DP; Neal KR; Hoiseth SK; Jansen KU; Anderson AS
Vaccine; 2010 Nov; 28(48):7667-75. PubMed ID: 20875489
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease.
Jacobsson S; Hedberg ST; Mölling P; Unemo M; Comanducci M; Rappuoli R; Olcén P
Vaccine; 2009 Mar; 27(10):1579-84. PubMed ID: 19162117
[TBL] [Abstract][Full Text] [Related]
11. Human antibody response to the 70-Kd common neisserial antigen in patients and carriers of meningococci or non-pathogenic Neisseria.
Aoun L; Lavitola A; Aubert G; Prère MF; Cremieux AC; Martin PM
Ann Inst Pasteur Microbiol; 1988; 139(2):203-12. PubMed ID: 3136782
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice.
Zarantonelli ML; Antignac A; Lancellotti M; Guiyoule A; Alonso JM; Taha MK
J Antimicrob Chemother; 2006 May; 57(5):924-30. PubMed ID: 16513914
[TBL] [Abstract][Full Text] [Related]
14. Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity.
Welsch JA; Moe GR; Rossi R; Adu-Bobie J; Rappuoli R; Granoff DM
J Infect Dis; 2003 Dec; 188(11):1730-40. PubMed ID: 14639545
[TBL] [Abstract][Full Text] [Related]
15. [Antibody response in subjects with meningococal disease and in healthy carriers of Neisseria meningitidis].
Natoli D; Tringali G; Puma G; Castellini S; Chiarini A
G Batteriol Virol Immunol; 1976; 69(1-6):64-70. PubMed ID: 828887
[TBL] [Abstract][Full Text] [Related]
16. [Studies on serum meningococcal antibodies in patients with meningococcal meningitis and a healthy population].
Pang HM
Zhonghua Yu Fang Yi Xue Za Zhi; 1988 Jul; 22(4):233-5. PubMed ID: 3146488
[No Abstract] [Full Text] [Related]
17. Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.
Harthug S; Rosenqvist E; Høiby EA; Gedde-Dahl TW; Frøholm LO
J Clin Microbiol; 1986 Dec; 24(6):947-53. PubMed ID: 3097068
[TBL] [Abstract][Full Text] [Related]
18. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease.
Idänpään-Heikkilä I; Høiby EA; Chattopadhyay P; Airaksinen U; Michaelsen TM; Wedege E
J Med Microbiol; 1995 Nov; 43(5):335-43. PubMed ID: 7562997
[TBL] [Abstract][Full Text] [Related]
19. Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock.
Jessouroun E; da Silveira IF; Larangeira AP; Pereira S; Fernandes SA; Rabinovitch L; Frasch CE; Castro-Faria-Neto HC; Bozza PT
Vaccine; 2004 Jun; 22(20):2617-25. PubMed ID: 15193387
[TBL] [Abstract][Full Text] [Related]
20. Rapid characterization of outer-membrane proteins in Neisseria lactamica by SELDI-TOF-MS (surface-enhanced laser desorption ionization-time-of-flight MS) for use in a meningococcal vaccine.
Mukhopadhyay TK; Halliwell D; O'Dwyer C; Shamlou PA; Levy MS; Allison N; Gorringe A; Reddin KM
Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):175-82. PubMed ID: 15315478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
